Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8801 results

  1. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTE10089 Expected publication date:  12 November 2026

    Health technology evaluations
    In development

  4. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 14 April 2026.

    In consultation

  6. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Infection prevention and control update

    In development Reference number: GID-QS10177 Expected publication date: TBC

    Quality standard
    In development

  9. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]

    Awaiting development Reference number: GID-TA11200 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development

  11. Bipolar disorder: assessment and management (extraordinary review)

    In development Reference number: GID-NG10380 Expected publication date: TBC

    NICE guideline
    In development

  12. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  13. Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

    Awaiting development Reference number: GID-TA11724 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development